↓ Skip to main content

Survival of patients with advanced metastatic melanoma: the impact of novel therapies–update 2017

Overview of attention for article published in European Journal of Cancer (1965), August 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (90th percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news
1 news outlet
policy
3 policy sources
twitter
6 X users
patent
2 patents
facebook
2 Facebook pages

Citations

dimensions_citation
240 Dimensions

Readers on

mendeley
220 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Survival of patients with advanced metastatic melanoma: the impact of novel therapies–update 2017
Published in
European Journal of Cancer (1965), August 2017
DOI 10.1016/j.ejca.2017.06.028
Pubmed ID
Authors

Selma Ugurel, Joachim Röhmel, Paolo A. Ascierto, Keith T. Flaherty, Jean Jacques Grob, Axel Hauschild, James Larkin, Georgina V. Long, Paul Lorigan, Grant A. McArthur, Antoni Ribas, Caroline Robert, Dirk Schadendorf, Claus Garbe

Abstract

The treatment of metastatic melanoma is still undergoing a process of major change. The two most important novel therapeutic strategies, selective kinase inhibitors and immune checkpoint blockers, both significantly prolong survival times of patients with advanced metastatic disease. Different agents, dose regimens and combinations have been tested against each other vigorously within these two groups. However, results from prospective head-to-head comparative studies of both strategies are still lacking. We performed an exploratory analysis of survival data from selected clinical trials representative for the new treatment strategies in advanced metastatic melanoma. Eighty-three Kaplan-Meier survival curves from 25 trials were digitised and grouped by therapeutic strategy and treatment line. For each of these groups, mean survival curves were generated for progression-free (PFS) and overall survival (OS) by weighted averaging. Survival curves grouped together by therapeutic strategy revealed a high concordance, particularly in the first-line setting. For kinase inhibitors, the most favourable PFS and OS in all therapy lines were observed for combined BRAF plus MEK inhibition. For immune checkpoint inhibitors, combined PD-1 plus CTLA-4 inhibition demonstrated the best survival outcome in all categories except for OS in first-line therapy. For the latter, combined PD-1 plus CTLA-4 inhibition showed similar outcomes as single-agent PD-1 inhibition. Comparison of kinase inhibitors and checkpoint blockers revealed a superiority of combined BRAF plus MEK inhibition within the first 6 months, later changing to a superiority of PD-1 blockers alone or in combination with CTLA-4 blockers. These results need confirmation by prospective clinical trials.

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 220 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 220 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 39 18%
Researcher 34 15%
Student > Bachelor 21 10%
Other 20 9%
Student > Master 19 9%
Other 37 17%
Unknown 50 23%
Readers by discipline Count As %
Medicine and Dentistry 76 35%
Biochemistry, Genetics and Molecular Biology 32 15%
Agricultural and Biological Sciences 18 8%
Immunology and Microbiology 10 5%
Pharmacology, Toxicology and Pharmaceutical Science 9 4%
Other 19 9%
Unknown 56 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 25. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 May 2022.
All research outputs
#1,516,331
of 25,461,852 outputs
Outputs from European Journal of Cancer (1965)
#302
of 6,879 outputs
Outputs of similar age
#29,545
of 325,268 outputs
Outputs of similar age from European Journal of Cancer (1965)
#5
of 101 outputs
Altmetric has tracked 25,461,852 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,879 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.1. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 325,268 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 101 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.